Non Hodgkin Lymphoma News and Research

RSS

Midpregnancy herbicide exposure linked to increased preterm birth risk

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

31 Jul 2026

Midpregnancy herbicide exposure linked to increased risk of preterm birth

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

22 Jul 2026

AACR report highlights unequal burden of cancer in the United States

The American Association for Cancer Research (AACR) today released its Cancer Disparities Progress Report 2026, a comprehensive analysis of the unequal burden of cancer in the United States.

24 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

New consortium aims to fast-track breakthroughs against follicular lymphoma

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not require immediate treatment.

1 Dec 2025

Common chemical tetrachloroethylene may be harmful to the liver

Liver disease is usually caused by one of three factors: alcohol consumption, fat buildup in the liver linked to obesity, diabetes and high cholesterol, or hepatitis B and C.

23 Oct 2025

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025

Nuclear missile workers are contracting cancer. They blame the bases.

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.

3 Oct 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

Immunoglobulin replacement therapy not associated with reduced risk of serious infections in patients with CLL

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

31 Jul 2025

Most dairy foods linked to neutral or better health but yogurt stands out for real benefits

A major scoping review of recent systematic reviews and meta-analyses finds that most dairy products are either neutral or modestly protective for heart, cancer, metabolic, and mortality outcomes in adults. Yogurt and other fermented dairy consistently show the strongest health associations, while some risks remain for specific cancers.

28 Jul 2025

VCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl transferase-1 (GGT-1), for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often treatment-resistant T-cell lymphoma.

26 Jul 2025

Air travel disrupts DNA repair in flight crew, raising cancer concerns

Researchers found that flight attendants show reduced DNA repair capacity and immune changes after air travel, which may help explain their higher cancer risk.

14 May 2025

Cancer rates are climbing in younger adults and researchers want to know why

A new NIH-led study finds rising rates of 14 cancer types in Americans under 50, especially breast, colorectal, kidney, uterine, and pancreatic cancers. The research urges deeper investigation into shared risk factors and earlier screening strategies.

8 May 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025